MarketResearchReports.Biz
presents this most up-to-date research on "Melanoma - Australia
Drug Forecast and Market Analysis to 2023"
Melanoma
is the deadliest and most aggressive form of skin cancer. The major
treatments for melanoma are categorized into immunotherapies and BRAF
mutation-targeted therapies. GlobalData estimates the 2013 sales for
melanoma at approximately $1.34 billion across the 8MM covered in
this report. The market will increase by four-fold over the forecast
period, reaching $5.64 billion in 2023 at a CAGR of 15.5%. This
growth will be driven by an increase in melanoma incident cases as
well as the approval and uptake of premium-priced products, such as
PD-1-targeting mAbs and BRAF/MEK inhibitor combinations. GlobalData
expects, by the end of the forecast period, the checkpoint
immunotherapy drug class to dominate the melanoma market (including
both BRAF wild-type and mutation-positive patient segments) with an
overall 67% share of the melanoma market.
GlobalData expects growth of
this market to be driven by increasing disease incident cases as the
population ages, the launch of expensive new therapies including
anti-PD-1 immunotherapies and BMS Yervoy/Opdivo combination, and the
label expansion of metastatic drugs into the adjuvant setting.
However, market growth in Australia is expected to be restricted by
the PBSs reimbursement watchdog, PBAC. At present, Zelboraf and
Mekinist have not been given approval from PBAC in Australia,
although patients can access Mekinist through a patient access
program. In addition, since the reimbursement approval of Tafinlar,
Yervoy is only reimbursed when given after BRAF/MEK inhibitor
treatment.
Download
Sample copy of this Report at :
http://www.marketresearchreports.biz/sample/sample/835147
Scope
- Overview of Melanoma
including epidemiology, etiology, symptoms, diagnosis, pathology and
treatment guidelines as well as an overview on the competitive
landscape.
- Detailed information on the
key drugs in Australia including product Melanomacription, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in Australia from 2013-2023.
- Analysis of the impact of key
events as well the drivers and restraints affecting Australia
Melanoma market.
Reasons to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the competition
by understanding the changing competitive landscape for Melanoma.
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2013-2023 in Australia.
Table
of Contents
1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 6
1.2 List of Figures 10
2 Introduction 12
2.1 Catalyst 12
2.2 Related Reports 13
2.3 Upcoming Related Reports 13
3 Disease Overview 14
3.1 Etiology and
Pathophysiology 14
3.1.1 Etiology 14
3.1.2 Pathophysiology 14
3.1.3 Melanoma Biomarkers 15
3.2 Clinical Staging 16
3.3 Symptoms 18
3.4 Prognosis 18
3.5 Quality of Life 20
4 Disease Management 21
4.1 Diagnosis Overview 21
4.2 Treatment Overview 22
4.2.1 Localized Melanoma: Stage
0 to Stage IIC 24
4.2.2 Regional Melanoma: Stage
IIIA to Stage IIIC 25
4.2.3 Unresectable and
Metastatic Melanoma: Stage III and Stage IV 28
4.3 Australia 35
4.3.1 Screening and Diagnosis
36
4.3.2 Clinical Practices 37
5 Competitive Assessment 40
5.1 Overview 40
5.2 Interferon-based Adjuvant
Therapies 42
5.2.1 Roferon-A (Interferon
Alfa-2a) 42
5.2.2 Intron A (Interferon
Alfa-2b) 46
5.2.3 Sylatron (Peginterferon
Alfa-2b) 51
5.3 Immune Checkpoint
Inhibitors 57
5.3.1 Yervoy (Ipilimumab) 57
5.3.2 Opdivo (Nivolumab) 67
5.3.3 Keytruda (Pembrolizumab)
76
5.4 BRAF Mutation-targeted
Therapies 84
5.4.1 Zelboraf (Vemurafenib) 84
5.4.2 Tafinlar (Dabrafenib) 91
5.4.3 Mekinist (Trametinib) 97
5.5 Other Therapeutic Classes
108
6 Unmet Need and Opportunity
Analysis 110
6.1 Overview 110
6.2 Therapeutic Options for
BRAF Wild-Type Patients 112
Follow
us on LinkedIn:
https://www.linkedin.com/company/marketresearchreports-biz
About
us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Contact
State
Tower
90
Sate Street, Suite 700
Albany,
NY 12207
Tel:
+1-518-621-2074
No comments:
Post a Comment